InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,071.63
(
0.02%
)
US TECH 100
16,899.20
(
-0.94%
)
Dow Jones
38,460.92
(
-0.11%
)
Brent Oil
87.51
(
0.33%
)
Bitcoin
63,887.50
(
-0.61%
)
Post# of 53906
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Tuff-Stuff

Send PM Follow Ignore
Followers 219
Posts 247348
Boards Moderated 2
Alias Born 04/06/2006

Tuff-Stuff

Re: Tuff-Stuff post# 46121

Friday, 01/02/2015 8:26:57 AM

Friday, January 02, 2015 8:26:57 AM

Post# of 53906
In a regulatory filing, Aldeyra Therapeutics (NASDAQ:ALDX) discloses that it has submitted an Investigational New Drug application to the FDA for the start of a Phase 2 study assessing its lead product candidate, NS2, for the treatment of the genetic disease Sjorgren-Larsson Syndrome.

Pray for A Pain Free Day!

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up